These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

134 related items for PubMed ID: 2573239

  • 1. Clinical melperone treatment blocks D2-dopamine receptors in the human brain as determined by PET.
    Wiesel FA, Farde L, Halldin C.
    Acta Psychiatr Scand Suppl; 1989; 352():30-4. PubMed ID: 2573239
    [Abstract] [Full Text] [Related]

  • 2. Plasma prolactin and central D2 receptor occupancy in antipsychotic drug-treated patients.
    Nordström AL, Farde L.
    J Clin Psychopharmacol; 1998 Aug; 18(4):305-10. PubMed ID: 9690696
    [Abstract] [Full Text] [Related]

  • 3. Central D1- and D2-receptor occupancy during antipsychotic drug treatment.
    Wiesel FA, Farde L, Nordström AL, Sedvall G.
    Prog Neuropsychopharmacol Biol Psychiatry; 1990 Aug; 14(5):759-67. PubMed ID: 1981395
    [Abstract] [Full Text] [Related]

  • 4. 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation.
    Kapur S, Zipursky RB, Remington G, Jones C, DaSilva J, Wilson AA, Houle S.
    Am J Psychiatry; 1998 Jul; 155(7):921-8. PubMed ID: 9659858
    [Abstract] [Full Text] [Related]

  • 5. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients.
    Nordström AL, Farde L, Wiesel FA, Forslund K, Pauli S, Halldin C, Uppfeldt G.
    Biol Psychiatry; 1993 Feb 15; 33(4):227-35. PubMed ID: 8097114
    [Abstract] [Full Text] [Related]

  • 6. Distribution of remoxipride to the human brain and central D2-dopamine receptor binding examined in vivo by PET.
    Farde L, von Bahr C.
    Acta Psychiatr Scand Suppl; 1990 Feb 15; 358():67-71. PubMed ID: 1978494
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone.
    Mamo D, Kapur S, Shammi CM, Papatheodorou G, Mann S, Therrien F, Remington G.
    Am J Psychiatry; 2004 May 15; 161(5):818-25. PubMed ID: 15121646
    [Abstract] [Full Text] [Related]

  • 11. Striatal vs extrastriatal dopamine D2 receptors in antipsychotic response--a double-blind PET study in schizophrenia.
    Agid O, Mamo D, Ginovart N, Vitcu I, Wilson AA, Zipursky RB, Kapur S.
    Neuropsychopharmacology; 2007 Jun 15; 32(6):1209-15. PubMed ID: 17077809
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics.
    Tauscher J, Hussain T, Agid O, Verhoeff NP, Wilson AA, Houle S, Remington G, Zipursky RB, Kapur S.
    Am J Psychiatry; 2004 Sep 15; 161(9):1620-5. PubMed ID: 15337652
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. An open label trial of raclopride in acute schizophrenia. Confirmation of D2-dopamine receptor occupancy by PET.
    Farde L, Wiesel FA, Jansson P, Uppfeldt G, Wahlen A, Sedvall G.
    Psychopharmacology (Berl); 1988 Sep 15; 94(1):1-7. PubMed ID: 3126517
    [Abstract] [Full Text] [Related]

  • 16. Striatal and extrastriatal dopamine D2 receptor occupancy by a novel antipsychotic, blonanserin: a PET study with [11C]raclopride and [11C]FLB 457 in schizophrenia.
    Tateno A, Arakawa R, Okumura M, Fukuta H, Honjo K, Ishihara K, Nakamura H, Kumita S, Okubo Y.
    J Clin Psychopharmacol; 2013 Apr 15; 33(2):162-9. PubMed ID: 23422369
    [Abstract] [Full Text] [Related]

  • 17. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects.
    Farde L, Nordström AL, Wiesel FA, Pauli S, Halldin C, Sedvall G.
    Arch Gen Psychiatry; 1992 Jul 15; 49(7):538-44. PubMed ID: 1352677
    [Abstract] [Full Text] [Related]

  • 18. The D2 receptor occupancy profile of loxapine determined using PET.
    Kapur S, Zipursky RB, Jones C, Remington GJ, Wilson AA, DaSilva J, Houle S.
    Neuropsychopharmacology; 1996 Dec 15; 15(6):562-6. PubMed ID: 8946430
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.